Scarica l'app Stockscreener
1.49
9.15%
-0.15
Dopo l'orario di chiusura:
1.54
0.05
+3.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.64
Aprire:
$1.66
Volume 24 ore:
4.67M
Relative Volume:
1.74
Capitalizzazione di mercato:
$541.46M
Reddito:
$1.21M
Utile/perdita netta:
$-177.12M
Rapporto P/E:
-1.8625
EPS:
-0.8
Flusso di cassa netto:
$-162.37M
1 W Prestazione:
+5.67%
1M Prestazione:
+37.96%
6M Prestazione:
+200.83%
1 anno Prestazione:
-11.83%
Intervallo 1D:
$1.45
$1.66
Intervallo di 1 settimana:
$1.41
$1.66
Portata 52W:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Nome
Lexicon Pharmaceuticals Inc
Settore
Industria
Telefono
(281) 863-3000
Indirizzo
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Confronta LXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.49 | 595.97M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-30 | Iniziato | Leerink Partners | Outperform |
| 2023-03-07 | Iniziato | Jefferies | Hold |
| 2022-08-12 | Iniziato | Piper Sandler | Overweight |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-18 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Downgrade | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Downgrade | Stifel | Buy → Hold |
| 2019-03-25 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Reiterato | Stifel | Buy |
| 2018-02-23 | Downgrade | Needham | Buy → Hold |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-01 | Reiterato | Wedbush | Outperform |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-05 | Reiterato | Wedbush | Outperform |
| 2016-08-02 | Iniziato | Citigroup | Buy |
| 2016-03-02 | Reiterato | Wedbush | Outperform |
| 2015-11-09 | Reiterato | Wedbush | Outperform |
| 2015-09-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Downgrade | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat
Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat
Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus
Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener
50M Americans with Chronic Pain: Lexicon Convenes Roundtable on Expanding Alternatives to PAIN Act - Stock Titan
Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com
Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Is Lexicon Pharmaceuticals Inc. stock bottoming out2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price actionGap Up & High Accuracy Investment Signals - newser.com
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st
Lexicon Pharmaceuticals, Inc. $LXRX Stake Reduced by Goldman Sachs Group Inc. - MarketBeat
What analysts say about Lexicon Pharmaceuticals Inc stockContrarian Investment Ideas & Big Gains Low Budget - earlytimes.in
Lexicon reports FDA's decision to extend review period for Zynquista - MSN
Lexicon Pharmaceuticals, Inc. $LXRX Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes - MarketScreener
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Lexicon awaits FDA feedback on diabetes drug application in Q4 By Investing.com - Investing.com Australia
Lexicon awaits FDA feedback on diabetes drug application in Q4 - Investing.com
Lexicon Pharmaceuticals (LXRX) Faces FDA Review Extension for Zy - GuruFocus
Lexicon pharmaceuticals announces update on submission of additional data to U.S. FDA - MarketScreener
Lexicon expects delay in FDA feedback on additional data for its diabetes drug - Reuters
Lexicon (LXRX) Seeks FDA Feedback on Zynquista with New Data Sub - GuruFocus
Lexicon Pharmaceuticals Provides Update on Zynquista NDA Resubmission Following FDA Feedback - Quiver Quantitative
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - The Manila Times
FDA Extends Review of Breakthrough Diabetes Drug Zynquista: What Lexicon's New Data Shows - Stock Titan
Lexicon Pharmaceuticals Inc Azioni (LXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexicon Pharmaceuticals Inc Azioni (LXRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):